Eli Lil­ly is re­join­ing the KRAS hunt.

The In­di­anapo­lis Big Phar­ma re­vealed Thurs­day, in an ab­stract for AACR, that it has been work­ing on a new small mol­e­cule to tar­get the in­fa­mous onco­gene and are plan­ning to put it in­to Phase I lat­er this year. It marks Lil­ly’s first pub­lic for­ay in­to the field in near­ly a year, since it ditched its first mol­e­cule af­ter see­ing dan­ger­ous side ef­fects in five pa­tients.

The new ab­stract opens with a pub­lic diss. Like the old mol­e­cule, Lil­ly’s new can­di­date goes af­ter KRASG12C, the same mu­ta­tion that Am­gen and Mi­rati have tar­get­ed in their late-stage pro­grams. Those may be on a path to ap­proval but, Lil­ly said, they’re pret­ty weak drugs.

“Cur­rent­ly, there are no FDA-ap­proved KRAS-G12C in­hibitors,” the com­pa­ny’s re­searchers wrote, “and those in clin­i­cal de­vel­op­ment have rel­a­tive­ly mod­est ac­tiv­i­ty com­pared to oth­er ap­proved ther­a­pies tar­get­ing oth­er clas­sic onco­genic dri­vers.”

There are da­ta to bear the claim out: Al­though doc­tors and sci­en­tists have want­ed a KRAS drug for decades, on­ly about 30% to 40% of lung can­cer pa­tients with the mu­ta­tion re­spond to Am­gen and Mi­rati’s drugs and their tu­mors on­ly stop grow­ing for about 6 to 7 months.

That may help thou­sands of pa­tients in the next decade, but it falls short of the ef­fect seen in oth­er tar­get­ed lung can­cer drugs. The drug has hard­ly worked at all on oth­er tu­mor types.

Lil­ly’s sci­en­tists at­trib­uted the meh re­sponse seen in many pa­tients in part to mol­e­cules that don’t com­plete­ly fill the tar­get pock­et on KRASG12C. They claimed their drug was much bet­ter at do­ing so. It’s over 25 times more po­tent than Am­gen’s, they wrote: You need 3.35 nanomo­lars of the Lil­ly mol­e­cule to re­duce the pro­tein’s ac­tiv­i­ty by 50%, com­pared with 89.9 nanomo­lars of the Am­gen mol­e­cule. You need 47.9 nanomo­lars of Mi­rati’s mol­e­cule.

They will have the chance to prove that dif­fer­ence trans­lates in­to the clin­ic lat­er this year. The re­searchers not­ed, though, what Am­gen and Mi­rati’s clin­i­cal da­ta have al­ready borne out: Not every tu­mor is equal­ly de­pen­dent on KRAS and, for many, a com­bi­na­tion ap­proach might be nec­es­sary.

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended nine drugs for approval this week while also giving thumbs up for six expanded indications, including Novo Nordisk’s approved obesity medication Wegovy for younger people. Wegovy is already approved as an obesity treatment in the EU for adults, and the new indication would allow prescriptions for adolescents aged 12 and older.

RNA biotech GreenLight Biosciences has been handed an offer for potential acquisition.

GreenLight said in a release that it has received a non-binding “indication of interest” from Fall Line Endurance Fund to acquire GreenLight’s capital stock for $0.60 per share in cash. The release said any potential agreement between the two parties would depend on certain conditions.

Through a special committee, the biotech will evaluate the offer but added there’s no certainty a deal will go forward. GreenLight will also not make any more announcements until a deal comes through or “otherwise determines” a statement is necessary.

A public T cell biotech’s chief executive has decided to leave the company.

TScan Therapeutics said Friday morning that CEO David Southwell stepped down earlier this week, leaving both his chief executive and board member roles. Filling in is Gavin MacBeath, the company’s CSO and COO. He became the acting CEO on Tuesday, and will continue to remain CSO and COO, TScan’s announcement read.